Published in Brain Stimulation Journal, study describes insights from world’s largest depression registry MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, announced today a new peer-reviewed paper, published in Brain Stimulation Journal and available online now. The paper
Good morning, and thank you for joining us for Neuronetics' First Quarter 2022 conference call. Joining me on today's call are Neuronetics' president and chief executive officer, Keith Sullivan; and the SVP chief financial officer and treasurer, Steve Furlong. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call will include forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to our business, strategy, financial and revenue guidance, the impact of COVID-19 and other operational issues and metrics.
Neuronetics (STIM) delivered earnings and revenue surprises of 0% and 7.43%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?